Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The hypoxia-inducible factor-1 (HIF-1) is a key regulator in the mammalian response to oxygen deficiency under both physiological and pathological conditions such as cancer. A number of studies indicated an association between tumor hypoxia, increased hypoxia-inducible factor (HIF-1alpha) levels and a poor prognosis. The HIF-1alpha regulation in response to hypoxia occurs primarily on the level of protein stability due to posttranslational hydroxylation. However, HIFalpha-subunits also respond to various growth factors, hormones, or cytokines under non-hypoxic conditions implicating the involvement of different kinase pathways in their regulation thereby increasing the interest in HIF-1alpha as a new drug target. Herein, we review current knowledge about phosphorylation-dependent HIF-1alpha regulation, HIF-1alpha protein-protein interactions and subcellular localization with emphasis on new therapeutic strategies targeting the HIF pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The major posttranslational modification appears to be the oxygen-dependent hydroxylation [16, 17] of two specific proline residues, Pro 402 and Pro 564, within the ODDD [17, 18] and of an asparagine residue, N 803, within the TAD-C of human HIF-1 [19].”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 1×
“The TSC1/TSC2 complex inhibits mTOR signaling indirectly by acting as a GTPase-activating protein (GAP) towards Rheb, a small GTPase Ras homolog enriched in brain [88-91].”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 1×
“Hydroxylation of the proline residues within the ODDD allows binding of the von HippelLindau tumor suppressor protein (pVHL) as part of an E3 ubiquitin ligase complex which subsequently leads to ubiquitination and proteasome-dependent degradation of HIF-1 [20-27].”
BackgroundAsparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 1×
“The major posttranslational modification appears to be the oxygen-dependent hydroxylation [16, 17] of two specific proline residues, Pro 402 and Pro 564, within the ODDD [17, 18] and of an asparagine residue, N 803, within the TAD-C of human HIF-1 [19].”
BackgroundGSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“At the same time, hypoxia has been reported to inhibit mTOR [86] via induction of the hypoxia-responsive gene REDD1 and subsequent activation of the tumor suppressor tuberous sclerosis heterodimeric complex TSC1/TSC2 [87].”
BackgroundMolecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Cited by
Metabolic zonation of the liver: The oxygen gradient revisited
Kietzmann, T. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.012 · Cited by 499
Self-citationPI3K/Akt and HIF‑1 signaling pathway in hypoxia‑ischemia (Review)
Zhang, Z., Yao, L., Yang, J., Wang, Z., & Du, G. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9375 · Cited by 404
Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved?
Görlach, A., Dimova, E. Y., Petry, A., Martínez-Ruiz, A., Hernansanz-Agustín, P., Rolo, A. P., Palmeira, C. M., & Kietzmann, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.016 · Cited by 351
Self-citationAntiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Kietzmann, T., Mennerich, D., & Dimova, E. Y. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00011 · Cited by 176
Self-citation
Metadata
- Authors
- Dimova, E., Michiels, C., & Kietzmann, T.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-11-01
- Volume
- 15
- Issue
- 33
- Pages
- 3867-3877
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2171003762
- Cited by
- 37
- References
- 27
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets. https://app.cochat.ai/papers/10.2174/138161209789649358
- The paper
- Dimova, E., Michiels, C., & Kietzmann, T. (2009). Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets. Current Pharmaceutical Design. https://doi.org/10.2174/138161209789649358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.